"Designing Growth Strategies is in our DNA"

Pembrolizumab Market Size, Share & Industry Analysis, By Product Type (KEYTRUDA IV and KEYTRUDA QLEX / SC Pembrolizumab), By Disease Indication (NSCLC, Melanoma, HNSCC, Urothelial Carcinoma, RCC, TNBC, Gastric/GEJ/Esophageal Cancers, Cervical Cancer, and Others), By Age Group (Pediatric and Adults), By Type (Branded and Biosimilar), By Therapy Setting (Early-stage / Perioperative, Advanced / Metastatic, and Others), By Route of Administration (IV and SC), By End User (Hospitals, Specialty Cancer Clinics, Ambulatory Infusion Centers, and Others), and Regional Forecast, 2026-2034

Last Updated: May 18, 2026 | Format: PDF | Report ID: FBI115937

 

  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann